Hydantoin

Quick links to important sections

Hydantoin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydantoin

Property Description
Active Ingredient (Class) Hydantoin derivatives (e.g., Phenytoin)
Form (Parent Compound) White crystalline solid (synthetic)
Pharmacological Class Anticonvulsant / Antiepileptic Drug (AED)
Common Use (Derivative) Management of specific seizure types
Origin Synthetically derived organic compound

Hydantoin is a five-membered heterocyclic organic compound, chemically described as a cyclic ureide. Its molecular structure is a synthetic fusion of features found in both urea and an amino acid. This base structure is the foundation for a class of important pharmacological agents known as hydantoin derivatives, which are critically relevant in the field of neurology.

The most widely recognized and clinically significant derivative is phenytoin. This compound is classified as an Antiepileptic Drug (AED). The primary medical use for this derivative is the treatment of certain types of seizures, including tonic-clonic and complex partial seizures. This means the drug class is a tool for doctors to help prevent seizure activity by stabilizing nerve membranes.

While the parent structure has been explored in the development of other biologically active compounds, its anticonvulsant properties remain its most critical medical application. Furthermore, the importance of this class is underscored by its status as an essential medicine, confirming its established global importance in healthcare.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus
  2. World Health Organization's Model List of Essential Medicines

What side effects are possible with Hydantoin?

Possible Side Effects and Safety Information

The use of hydantoin-class medications is associated with a range of documented side effects, from common, dose-related neurological effects to rare but serious systemic reactions.


Serious and Clinically Significant Adverse Reactions

Official regulatory documents emphasize the potential for severe, life-threatening events, including serious dermatologic reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The drug must be discontinued immediately at the first sign of a rash or other potential symptom. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a multiorgan hypersensitivity reaction that can be fatal, has also been reported.

Other serious risks include acute hepatotoxicity (liver damage/failure), hematopoietic complications (e.g., agranulocytosis, aplastic anemia), and cardiac effects (e.g., bradycardia, severe hypotension, cardiac arrest), particularly with rapid intravenous administration. Hydantoins are part of a drug class linked to an increased risk of suicidal behavior and ideation.

Common Adverse Reactions and Safety Patterns

The most common adverse reactions are related to the central nervous system and are often dose-dependent, including nystagmus (uncontrolled eye movements), ataxia (loss of coordination), slurred speech, confusion, and dizziness. These effects generally correlate with serum levels exceeding the established therapeutic range.

Restrictions and Monitoring

Hydantoin is contraindicated in patients with a history of hypersensitivity to the drug or other hydantoins, and in patients with specific cardiac conditions, such as second- or third-degree A-V block or Adams-Stokes syndrome. Abrupt discontinuation in patients with epilepsy may precipitate status epilepticus; dosage changes must be performed gradually. Special monitoring is warranted for pregnant patients (due to teratogenicity risk), patients with renal or hepatic impairment, and slow metabolizers of the drug.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes officially documented signs of overdose and regulator-mandated emergency actions for Hydantoin derivatives (e.g., Phenytoin).

Documented Overdose Manifestations
Overdose is primarily defined by a spectrum of Central Nervous System (CNS) toxicity, beginning with mild signs such as nystagmus (involuntary eye movement), ataxia (unsteadiness), and dysarthria (slurred speech). As toxicity progresses, patients may exhibit lethargy, mental confusion, tremor, and vomiting.
Severe Outcomes and Required Actions
Severe toxicity is officially documented to lead to life-threatening complications, including profound CNS depression (coma and respiratory depression) and significant cardiovascular toxicity. The latter can present as severe hypotension, bradycardia, cardiac arrhythmias, and cardiac arrest, especially following rapid intravenous exposure.
Emergency Response Statement
Regulatory labeling explicitly requires individuals to seek immediate medical attention or contact emergency services if any signs of toxicity develop. There is no known specific antidote for Hydantoin overdose. Management is limited to symptomatic and supportive care, which includes continuous electrocardiogram (ECG) and blood pressure monitoring, along with checks of serum drug levels. Special considerations are noted for elderly or gravely ill patients, who face increased risks of severe cardiotoxic reactions.

Therapeutic Uses of Hydantoin

Quick Facts

  • May assist in managing: Partial-onset seizures and tonic-clonic seizures.
  • Used as a component in treatments for: Certain types of cardiac arrhythmias.
  • Derivative forms may be indicated for: Malignant hyperthermia and specific cancers.

What Hydantoin Treats: Main Uses and Benefits

Compounds containing the hydantoin molecular structure are utilized in several distinct therapeutic areas. The primary approved uses center on neurological health, where hydantoin derivatives serve as anticonvulsants. These derivatives may help manage and reduce the occurrence of seizures associated with epilepsy, particularly partial-onset seizures and generalized tonic-clonic seizures. This class of medication is considered an available option for individuals requiring seizure management.

Beyond seizure control, specific derivatives of hydantoin are indicated for other conditions. For example, related compounds may provide benefit as antiarrhythmic agents to manage certain types of cardiac rhythm disturbances. Furthermore, other approved hydantoin derivatives are utilized in oncology to treat specific hormone-sensitive cancers, and as a skeletal muscle relaxant to manage conditions like malignant hyperthermia. This chemical scaffold supports various medications that may contribute to the management of these conditions.

Regulatory References

  1. NIH MedlinePlus guidance on Phenytoin

Eligibility and Restrictions for Use

The official eligibility profile for hydantoin derivatives, such as phenytoin, is defined by strict regulatory criteria based on patient physiology and medical history.

Absolute Contraindications

The medicine is absolutely contraindicated for individuals with a known hypersensitivity to any hydantoin or a history of prior acute hepatotoxicity caused by the drug. Use is also prohibited for patients with certain severe cardiac conduction defects (e.g., specific heart block) when the medication is administered intravenously. Co-administration with the antiretroviral delavirdine is also prohibited by regulatory labels.

Restricted and Conditional Use

Regulators generally state the drug is not recommended for use in pregnant women due to established risks of congenital malformations, and recommend effective contraception for women of childbearing potential. Patients with hepatic or renal impairment require caution and monitoring due to altered drug clearance. While the drug is approved for adults and children, use in the elderly requires caution because clearance may be decreased. Furthermore, individuals with specific genetic markers (e.g., HLA-B*15:02) face restrictions due to an increased risk of severe skin reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile of hydantoin derivatives, such as phenytoin, is largely defined by its function as a potent inducer of hepatic enzymes. Its metabolism occurs primarily through the CYP2C9 and CYP2C19 enzymes, which creates the potential for altering the exposure of various co-administered medicinal products.

Specific restrictions on co-administration are documented. The combination of phenytoin with Delavirdine is formally contraindicated in regulatory labeling due to the risk of virologic failure. Furthermore, the prescribing information advises that phenytoin should not be administered concomitantly with enteral feeding preparations or related nutritional supplements, as this action is associated with lower than expected phenytoin serum levels.

Interaction patterns with certain substances are concentration-dependent. Acute alcohol intake is officially documented to potentially increase phenytoin serum levels, while chronic alcohol use may cause a decrease. Co-administration with some antiepileptic drugs, including valproic acid, has an officially described unpredictable effect on phenytoin concentrations. Caution is also noted for interpreting total plasma concentrations in patients with renal or hepatic disease, where an increased fraction of unbound drug affects the concentration relevance.

Mechanism of Action

The pharmacological action of the hydantoin derivative, Phenytoin, is achieved through a targeted interaction with the core machinery of neuronal excitability, the voltage-gated sodium channels ( Nav channels).

State-Dependent Blockade of Sodium Channels

The primary mechanistic domain involves the drug acting as a blocker that preferentially engages the Nav channels when they are in their inactive (refractory) state. This interaction prolongs the refractory period, which influences the speed and frequency of nerve impulses.

Selective Suppression of Pathological Neural Firing

Phenytoin operates with use-dependence, meaning its blocking effect is significantly intensified when the Nav channels are used repeatedly at high frequencies, as occurs during periods of pathological hyperexcitability. This selectivity for overactive neurons results in the stabilization of the neuronal membrane. This use-dependence ensures the blockade has a greater proportional effect on high-frequency action potentials than on those occurring at normal frequencies.

Inhibition of Abnormal Signal Propagation

The resulting physiological effect of the channel stabilization is the suppression of sustained repetitive firing (SRF), which reduces the electrical conductivity of the dysregulated cells. This cascade limits the spread of the electrical signal from its origin, reducing the propagation of the signal to adjacent neural tissue.

Dosage and Administration Information

The use of hydantoin derivatives, such as phenytoin, follows standardized administration principles. The primary approved delivery methods are oral and intravenous (IV). Oral administration, utilizing capsules, tablets, or suspension, is typically reserved for long-term maintenance therapy and may involve once-daily dosing for extended-release forms or divided doses up to three times per day. The IV route is used for acute conditions, as the intramuscular (IM) route is generally discouraged due to erratic absorption patterns.

When administering the drug intravenously, such as in acute conditions like status epilepticus, a high loading dose is often given (e.g., 10 to 15 mg/kg IV) to rapidly reach effective blood concentrations, followed by a lower maintenance regimen. Maintenance dosing is generally in the range of 200 to 500 mg daily, depending on the formulation and clinical needs.

Administration requires adherence to specific procedural constraints. Extended-release capsules must be swallowed whole to ensure proper absorption patterns. For the IV route, the injection solution must be diluted in 0.9% sodium chloride and infused at a controlled speed, generally not exceeding 50 mg per minute in adults. Dose adjustments or discontinuation of therapy are performed gradually over time, with new dosing levels typically evaluated after a period of 7 to 10 days to ensure stable drug concentrations. It is also noted that older adults may require lower or less frequent dosing schedules.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hydantoin


Evidence for Use in Partial-Onset Seizures

Research has extensively explored the use of hydantoin derivatives in people experiencing partial-onset seizures, which are conditions characterized by fluctuating or episodic manifestations. A variety of studies, including controlled trials, have applied this compound in research contexts involving fluctuating or unstable symptoms, with the goal of monitoring physiological strain or stress.

Studies conducted during periods of increased symptom activity have examined how hydantoin relates to outcomes describing episodic or acute changes. The research highlights changes measured during the study period, and the findings describe patterns observed in the studies. For this area of study, research describes patterns observed in the populations examined, and research provides insight into short-term changes. However, results apply only to the populations studied, and evidence quality varies across studies, meaning certainty remains low regarding individual outcomes.

Evidence for Use in Generalized Tonic-Clonic Seizures

Hydantoin was studied for its application in conditions associated with acute or disruptive episodes, such as generalized tonic-clonic seizures. Research has examined outcomes reflecting daily functioning or activity level, primarily in short-term studies focusing on episodes where symptoms become more noticeable.

The evidence contributes to understanding symptom patterns, with findings that indicate patterns observed in relation to the frequency of these episodes in the observed settings. Studies monitored patient-reported outcomes describing perceived discomfort and outcomes capturing phases of heightened symptom activity.

Long-term Studies and Follow-up

Research has also explored the longer-term effects of hydantoin use. Evidence so far suggests patterns observed across longer study durations, but long-term effects are not fully established. Follow-up durations were limited in many of the initial trials, and there is limited information for long-term outcomes and the durability of any observed response beyond a few years. Findings describe group patterns, not personal outcomes.

Evidence in Specific Patient Populations

Hydantoin was evaluated in studies observing responses across specific patient populations, including children and older adults. Data for certain groups remain insufficient, and subgroup findings are uncertain due to typically smaller sample sizes. Regarding pregnancy-related populations, evidence is limited, and research has focused on understanding symptom intensity or variability.

What is Still Uncertain About Hydantoin

Despite decades of research, significant uncertainties remain in the evidence landscape for hydantoin. Studies exploring short-term symptom changes was associated with mixed findings in some research. There is a gap in research concerning the duration over which the compound was studied, and limited information for long-term outcomes persists as a major concern. Finally, while research describes what has been observed so far, many results apply only to the populations studied, meaning generalizability to the broader population is uncertain.

Frequently Asked Questions (FAQ)

Common questions about Hydantoin (FAQ)

Q: How quickly does Hydantoin start working after I begin taking it?

Official prescribing information indicates that for acute, immediate needs, the drug is given intravenously with a loading dose to achieve effective levels rapidly. For routine, long-term use taken by mouth, dosage changes are typically evaluated after a period of 7 to 10 days. This period is necessary for the drug’s concentration in the body to stabilize.


Q: Can Hydantoin cause mood changes or depression?

Regulatory documents for antiepileptic drugs, including Hydantoin, include warnings about the risk of suicidal thoughts or behavior. Specific adverse reaction lists also document the potential for depression and insomnia. Regulatory documents indicate that patients should be monitored for any new or worsening changes in mood or behavior while taking this medication.


Q: Do I need to get blood tests done while on Hydantoin?

Official medical guidance emphasizes the need for careful monitoring with this class of medication. Healthcare providers typically schedule regular blood tests to measure the drug’s concentration, known as the serum level, in the body. This monitoring helps healthcare providers manage drug levels and reduce the potential risk of toxicity or loss of seizure control.


Q: Is it true that Hydantoin can affect gum health?

Regulatory adverse reaction lists indicate that the use of Hydantoin can be associated with gingival problems, which include tenderness, swelling, or minor bleeding of the gums. In conjunction with this reported effect, official patient information often emphasizes the importance of diligent dental hygiene practices.


Q: Can Hydantoin affect my ability to drive or operate machinery?

Official documents describe Central Nervous System (CNS) adverse reactions that may occur while using this medicine. These include effects like dizziness, unsteadiness, confusion, and drowsiness. Regulatory warnings indicate that caution should be exercised regarding activities requiring mental alertness, such as driving or operating heavy machinery.


Q: What does the term 'therapeutic range' mean in relation to Hydantoin?

The therapeutic range refers to the concentration level of the drug in the blood that is generally associated with a favorable benefit-risk profile. Maintaining the drug level within this established range helps healthcare providers manage the drug levels and reduce the potential risk of toxicity.


Q: Does Hydantoin affect bone density?

Studies and official information have noted an association between Hydantoin use and a potential reduction in bone density, sometimes referred to as osteopenia. This risk is particularly relevant for patients receiving long-term treatment. Furthermore, the medicine may also be associated with decreased levels of Vitamin D and folic acid in the body.


Q: Is Hydantoin the same kind of medicine as other seizure drugs?

Hydantoin derivatives are classified into a specific pharmacological group known as the hydantoin anticonvulsants. It is one of the original and older drugs used for managing seizures, which differentiates it chemically and historically from newer antiepileptic medications.


Q: Does Hydantoin have a risk of addiction or dependence?

The derivative phenytoin is generally not classified as a federally controlled substance by the U.S. Drug Enforcement Administration. Official labeling does not contain warnings about potential drug abuse or physical dependence. However, as with many antiepileptic drugs, a caution is noted regarding the risk of suicidal behavior and ideation.


Q: Are there any long-term effects of taking Hydantoin that I should know about?

Official regulatory documents describe a few long-term effects observed with the use of this medication. These include an associated risk of osteopenia (reduced bone mass) and peripheral polyneuropathy, which is nerve damage that primarily affects sensation. These patterns have been noted in individuals who have received long-term treatment.


Q: Is it normal to feel a bit tired when first starting Hydantoin?

Yes, regulatory documents list somnolence, which is the medical term for drowsiness, and fatigue as common neurological adverse reactions. These effects are often reported when treatment is initiated or following a dosage change.


Q: Can Hydantoin interact with my birth control pills?

Official prescribing information indicates that Hydantoin can interact with hormonal contraceptives, including birth control pills. The medicine may reduce the blood levels and intended effects of these hormonal products. The interaction is associated with a risk of reduced contraceptive effectiveness.


Q: Are there any specific foods or drinks to avoid while using Hydantoin?

Regulatory guidance specifically advises against giving the liquid suspension form with enteral feeding preparations (tube feeds) as this can lower the drug's blood level. Additionally, official information states that using the drug together with food may alter its effects.


Q: What kind of specialist usually prescribes Hydantoin?

As an antiepileptic medication, Hydantoin is prescribed by licensed healthcare professionals involved in the management of seizure disorders. This often includes neurologists, who specialize in the nervous system, but may also include other providers such as primary care providers.


Q: Is Hydantoin a controlled substance?

The primary derivative of the drug, phenytoin, is not classified as a federally controlled substance by the U.S. Drug Enforcement Administration.


Q: What is the difference between Hydantoin and Phenytoin?

Hydantoin refers to the parent chemical structure and the class name for this group of medications. Phenytoin is the specific and most widely used active drug that is derived from the Hydantoin base structure.


Q: What should I do if I forget to take a dose of Hydantoin?

Official patient instructions generally describe taking the missed dose as soon as it is remembered, unless it is close to the time of the next scheduled dose, in which case the missed dose is omitted. It is specifically instructed not to double the dose to compensate for a forgotten one.


Q: Are there any studies looking at Hydantoin for conditions other than its main use?

Regulatory documents clearly define the official indications, which are the treatment of specific seizure types (such as tonic-clonic and complex partial seizures). The drug is also officially indicated for the prevention of seizures during or following neurosurgery.


Q: Can Hydantoin be crushed or split if it's a tablet?

Regulatory guidance specifically states that extended-release capsules must be swallowed whole to ensure the medication is absorbed correctly. Official information does not provide explicit instructions for crushing or splitting standard tablets. An oral liquid suspension formulation exists.


Q: Is there a generic version of Hydantoin available?

Yes, the active drug derived from the Hydantoin class, phenytoin, is available in both generic and various brand-name formulations.


Q: Can Hydantoin cause weight gain or weight loss?

Based on adverse event reporting in official documents, weight loss is listed as a documented side effect associated with the use of this medication.


Q: Are there any known issues with Hydantoin and kidney function?

Regulatory information advises that caution is necessary for patients who have impaired renal (kidney) function. In these individuals, the proportion of free drug in the bloodstream may increase, which is associated with an increased risk of toxicity.


Q: What happens in a Hydantoin overdose?

An overdose is typically characterized by dose-related Central Nervous System effects. These can include uncontrolled eye movements (nystagmus), lack of muscle coordination (ataxia), and severe drowsiness, potentially advancing to confusion or coma. Cardiovascular issues such as low blood pressure or slowed heart rate are also possible.


Q: What is the research status of Hydantoin compared to newer medicines?

Hydantoin is classified as one of the older, or first-generation, antiepileptic drugs (AEDs). Official literature often describes newer AEDs as having different characteristics, such as potentially fewer drug interactions, when compared to first-generation medicines like Hydantoin.


Q: Are there specific vitamins or supplements that interact with Hydantoin?

Official information suggests that use of this drug may be associated with decreased levels of certain vitamins, including Vitamin D and folic acid. Regulatory guidance indicates that patients should inform their healthcare provider about all vitamins, supplements, and herbal products being used.


Q: If I have a history of allergies, can I still take Hydantoin?

Official regulatory guidance lists a known hypersensitivity (severe allergic reaction) to Hydantoin or other hydantoin-class drugs as an absolute contraindication. General patient safety guidelines describe informing a healthcare provider of any and all allergies before starting this medication.


Q: What are the most common reasons a doctor might choose Hydantoin over another medicine?

Hydantoin is recognized for its established role in healthcare, as evidenced by its inclusion on the World Health Organization's Model List of Essential Medicines. Its use is specifically indicated for treating tonic-clonic and complex partial seizures.


Q: Is there a maximum dose of Hydantoin described in official documentation?

Official documentation provides specific limits on how the medication is administered. For instance, the maximum rate for intravenous administration is strictly defined as not exceeding 50 mg per minute in adults. Routine oral maintenance dosing is typically cited as a range (e.g., 200 to 500 mg daily) intended to keep the drug concentration within the therapeutic range.


Q: Can Hydantoin affect sleep patterns?

Yes, official documents list several adverse effects that can impact sleep. These include insomnia (difficulty falling or staying asleep), drowsiness (somnolence), and dizziness.


Q: Why is Hydantoin sometimes mentioned in discussions about heart rhythm?

The medicine is mentioned in discussions about heart rhythm because it is contraindicated (prohibited) for use in patients with certain severe cardiac conditions, such as specific heart blocks or very slow heart rate. Furthermore, rapid administration of the drug intravenously has been linked to severe cardiac effects, including arrhythmias (irregular heartbeats).


Q: Can Hydantoin cause skin rashes or sensitivity to the sun?

Official adverse reaction reports indicate the potential for general skin issues, including skin rashes, hives, and itching. Furthermore, the FDA label also contains reports of a photosensitivity reaction, which means increased sensitivity to light, often from the sun.


Q: What are the signs that Hydantoin might not be working for someone?

The most direct sign of a loss of effectiveness would be a worsening of seizure control. Additionally, if monitoring reveals that the drug’s level in the bloodstream is below the established therapeutic range, this may also indicate a potential loss of expected control.


Q: Is it necessary to take Hydantoin with food?

Official regulatory documents mention that taking the drug together with food may alter its effects. While there is no strict instruction on whether to take it with or without a meal, consistent administration is emphasized to maintain stable drug levels. The liquid form is also known to interact with enteral feeds.


Q: Does Hydantoin interact with herbal remedies like St. John's Wort?

The FDA label does not explicitly name every possible herbal remedy, but official guidance broadly advises that patients should inform their healthcare provider about all vitamins and herbal products being used. This is due to the known potential for Hydantoin to interact with other substances.

How should Hydantoin be stored and disposed of?

How to Store and Dispose of Hydantoin (Phenytoin)

Storage and disposal requirements for phenytoin, a primary hydantoin derivative, are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Protect from moisture and light. Do not freeze oral suspension.
Container Keep in a tight, light-resistant container, tightly closed.
Safety Keep out of the sight and reach of children.

Disposal

All unused product and containers must be disposed of in accordance with local, regional, and national regulations. This instruction mandates compliance with established pharmaceutical waste protocols and requires that the product not be released into drains or the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hydantoin found in:

A-Z Index: